相似文献
1
Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
Emerg Infect Dis. 2021 Feb;27(2):636-638. doi: 10.3201/eid2702.201960. Epub 2020 Dec 21.
2
Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
Emerg Infect Dis. 2021 Feb;27(2):628-631. doi: 10.3201/eid2702.204088.
3
Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure.
Infect Control Hosp Epidemiol. 2020 Dec;41(12):1441-1442. doi: 10.1017/ice.2020.390. Epub 2020 Aug 3.
4
Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020.
Emerg Infect Dis. 2021 Feb;27(2):666-669. doi: 10.3201/2702.204480.
5
Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India.
Emerg Infect Dis. 2021 Feb;27(2):586-589. doi: 10.3201/eid2702.203938.
6
Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Clin Microbiol Infect. 2021 Mar;27(3):470.e1-470.e9. doi: 10.1016/j.cmi.2020.11.009. Epub 2020 Nov 20.
7
Prevalence of COVID-19 Virus Infection in Semnan province.
Iran J Immunol. 2021 Mar;18(1):74-81. doi: 10.22034/iji.2021.87670.1826.
8
Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran.
Iran J Immunol. 2021 Mar;18(1):82-92. doi: 10.22034/iji.2021.88168.1851.
9
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Lancet Infect Dis. 2021 Apr;21(4):473-481. doi: 10.1016/S1473-3099(20)30858-6. Epub 2020 Dec 15.
10
SARS-CoV-2 Infection and Mitigation Efforts among Office Workers, Washington, DC, USA.
Emerg Infect Dis. 2021 Feb;27(2):669-672. doi: 10.3201/eid2702.204529.
引用本文的文献
1
National and sub-national sero-epidemiology of immunoglobulin G against SARS-CoV-2 in Iran in 2021.
PLoS One. 2025 Jul 31;20(7):e0313795. doi: 10.1371/journal.pone.0313795. eCollection 2025.
2
Dynamics of SARS-CoV-2 Immunoglobulin G Antibody Among Hospitalized Patients and Healthcare Workers During the Delta Wave in Bangladesh.
Cureus. 2025 Apr 13;17(4):e82175. doi: 10.7759/cureus.82175. eCollection 2025 Apr.
3
Estimation of Anti-SARS-CoV-2 IgM/IgG Seroprevalence Among Non-Vaccinated and Vaccinated University Students: A Cross-Sectional Egyptian Study.
Viruses. 2025 Mar 6;17(3):378. doi: 10.3390/v17030378.
4
Evidence of rapid rise in population immunity from SARS-CoV-2 subclinical infections through pre-vaccination serial serosurveys in Pakistan.
J Glob Health. 2025 Feb 21;15:04078. doi: 10.7189/jogh.15.04078.
5
Signs and symptoms of covid - 19 in patients with a history of coronary artery bypass grafting surgery.
BMC Infect Dis. 2024 Feb 22;24(1):241. doi: 10.1186/s12879-024-09090-w.
6
Adjustment for collider bias in the hospitalized Covid-19 setting.
Glob Epidemiol. 2023 Aug 23;6:100120. doi: 10.1016/j.gloepi.2023.100120. eCollection 2023 Dec.
7
COVID-19 Subclinical Infection and Immunity: A Review.
Niger J Med. 2021 Nov-Dec;30(6):631-636. doi: 10.4103/njm.njm_85_21.
8
Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic.
J Public Health Afr. 2023 Jun 5;14(8):2315. doi: 10.4081/jphia.2023.2315. eCollection 2023 Aug 7.
9
Seroprevalence of COVID-19 in Oran: Cross-Sectional Study.
Microbiol Spectr. 2023 Aug 17;11(4):e0087623. doi: 10.1128/spectrum.00876-23. Epub 2023 Jun 7.
10
Overview of SARS-COV-2 infection at the Butantan Penitentiary Progression Center.
Rev Saude Publica. 2023 May 26;57(suppl 1):10s. doi: 10.11606/s1518-8787.2023057004717. eCollection 2023.
本文引用的文献
1
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Lancet. 2020 Aug 22;396(10250):535-544. doi: 10.1016/S0140-6736(20)31483-5. Epub 2020 Jul 6.
2
Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity.
Emerg Infect Dis. 2020 Sep;26(9):1978-1986. doi: 10.3201/eid2609.201840. Epub 2020 Jun 16.
3
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
Lancet. 2020 Aug 1;396(10247):313-319. doi: 10.1016/S0140-6736(20)31304-0. Epub 2020 Jun 11.
4
Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients.
Clin Microbiol Infect. 2020 Aug;26(8):1082-1087. doi: 10.1016/j.cmi.2020.05.023. Epub 2020 May 28.
5
Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.
JAMA. 2020 Jun 16;323(23):2425-2427. doi: 10.1001/jama.2020.8279.
6
Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020.
Euro Surveill. 2020 Mar;25(12). doi: 10.2807/1560-7917.ES.2020.25.12.2000256.
7
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.
N Engl J Med. 2020 May 21;382(21):2012-2022. doi: 10.1056/NEJMoa2004500. Epub 2020 Mar 30.
8
Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department.
J Med Virol. 2020 Oct;92(10):1724-1727. doi: 10.1002/jmv.25800. Epub 2020 Apr 8.
9
Inverse probability weighting.
BMJ. 2016 Jan 15;352:i189. doi: 10.1136/bmj.i189.
Zotero 插件